Goodsurance

Drug prices & Part D

CMS Issues First Draft Rules on How Drugmakers Must Honor 2028 Negotiated Prices for Infused and Injected Drugs

New draft guidance addresses for the first time how manufacturers must deliver negotiated Maximum Fair Prices to the clinics and provider offices that administer drugs, not just pharmacies that dispense them.

By the Goodsurance editorial teamJuly 12, 2026

The Centers for Medicare and Medicaid Services released draft guidance on July 16, 2026, explaining how manufacturers of certain Medicare drugs must deliver negotiated prices to health care providers for medications patients receive in clinical settings rather than picking up at a pharmacy.

The guidance covers the initial price applicability year 2028 and focuses on drugs under Medicare Part B, which pays for medications administered in doctors' offices, hospital outpatient departments, dialysis centers, and similar settings. Earlier guidance addressed how negotiated prices flow through pharmacies under Part D. This document tackles the more operationally complex provider channel.

Under the Inflation Reduction Act of 2022, CMS can negotiate prices on high-cost drugs with no generic or biosimilar competition. Manufacturers of selected drugs must make the Maximum Fair Price available to those who purchase and administer them. For Part B drugs, CMS plans to route transactions through a government-created intermediary called the Medicare Transaction Facilitator.

The draft guidance is open for public comment through September 18, 2026. CMS said it builds on final guidance for Part D drugs published in September 2025.

For beneficiaries, Part B drugs carry a standard 20 percent cost-sharing requirement under original Medicare, though supplemental coverage and Medicare Advantage plans alter what enrollees actually pay.

In plain words

Some medicines are not picked up at a pharmacy. They are given as shots or drips at a doctor's office or clinic. Medicare pays for these under Part B. New draft rules from CMS explain how drug companies must charge Medicare the lower, agreed-upon price when a provider gives patients one of these medicines. A government helper called the Medicare Transaction Facilitator will process the payments. This applies starting in 2028. The public can send comments until September 18, 2026.

Source: CMS
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

KFF: Medicare Advantage Drug Plans Received Over 600 Dollars Per Member in Rebates That Standalone Drug Plans Cannot Access

A KFF analysis explains the structural payment asymmetry that makes it harder for standalone Part D plans to compete on drug premiums, as the number of those plans hits record lows ahead of open enrollment.

August 8, 2026

Drug prices & Part D

Bipartisan Senate Bill Would Preserve Drug Discounts for Safety-Net Hospitals and Shut Down a Rebate Pilot

Six senators from both parties introduced the SUSTAIN 340B Act on August 5, proposing to protect point-of-purchase drug discounts for safety-net providers while adding new transparency and audit requirements.

August 6, 2026

Drug prices & Part D

CMS Counted a 2020 Reclassification Date for Creon, Delaying Medicare Price Talks by Years, Report Says

Public Citizen says CMS allowed AbbVie to use the date Creon was reclassified as a biologic rather than its original FDA approval date, pushing the drug's eligibility for Medicare price negotiation years into the future.

August 5, 2026

Drug prices & Part D

Medicare Part D Deductible Rises to 700 Dollars and Out-of-Pocket Drug Cap Reaches 2,400 Dollars for 2027

The Inflation Reduction Act tied the Medicare Part D annual deductible and catastrophic spending limit to drug cost growth, and both parameters rise again for 2027, continuing an upward pattern as specialty and GLP-1 drug spending climbs across the program.

August 4, 2026

Drug prices & Part D

Medicare and Drug Manufacturers Are Holding Negotiation Meetings This Summer on 15 High-Cost Drugs, With Final Prices Due by November

The third cycle of Medicare drug price negotiations is in its most active phase, with CMS and participating manufacturers in sessions that must conclude by November 1, 2026, to set maximum fair prices on cancer, HIV, and other specialty drugs taking effect in 2028.

August 3, 2026

Drug prices & Part D

CMS Confirms the 2027 Medicare Part D Base Premium at 41 Dollars and 33 Cents as a Federal Stabilization Subsidy for Drug Plans Ends

The confirmed base premium equals the maximum 6 percent annual increase the Inflation Reduction Act allows, but consumer advocates warn that actual plan-level premiums, which are set above that floor, are likely to climb sharply once a temporary federal subsidy expires at year-end.

July 30, 2026